Reference health
Ex-Post Analysis of Pharmaceutical Merger Cases in the EU and US: The Identification of the Relevant R&D Projects
19/19 checkable references clean · checked 2026-08-18
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
35 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 19 checked references that resolve
resolves10.1377/hlthaff.25.2.420
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
resolves10.1086/675862
Did Robert Bork Understate the Competitive Impact of Mergers? Evidence from Consummated Mergers
resolves10.1016/S1470-2045(17)30429-1
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
resolves10.1093/joclec/nhs019
ANTICOMPETITIVE STUMBLING STONES ON THE WAY TO A CLEANER WORLD: PROTECTING COMPETITION IN INNOVATION WITHOUT A MARKET
resolves10.1016/j.vaccine.2015.12.076
Status of vaccine research and development of vaccines for herpes simplex virus
resolves10.21037/tcr.2018.10.06
EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
resolves10.1007/s10842-016-0225-0
Empirical Analysis of the Assessment of Innovation Effects in U.S. Merger Cases
resolves10.1016/j.ejca.2018.08.005
How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma
resolves10.2147/DDDT.S119162
Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
The 35 references without a DOI — listed, not checked
no DOI — not checkedref1
no DOI — not checkedRecent advances in migraine therapy
no DOI — not checkedref4
no DOI — not checkedref6
no DOI — not checkedWhy We Need to Measure the Effect of Merger Policy and How to Do It
no DOI — not checkedTwo Puzzles Resolved: Of the Schumpeter-Arrow Stalemate and Pharmaceutical Innovation Markets
no DOI — not checkedTowards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown
no DOI — not checkedref14
no DOI — not checkedref17
no DOI — not checkedref18
no DOI — not checkedref19
no DOI — not checkedGuidelines on the applicability of Article 101 of the Treaty on the Functioning of the European Union to horizontal co-operation agreements
no DOI — not checkedref21
no DOI — not checkedref22
no DOI — not checkedPress Release: Mergers: Commission approves acquisition of GSK's oncology business by Novartis, subject to conditions
no DOI — not checkedFederal Trade Commission [FTC] (2000e): In the Matter of Glaxo Wellcome PLC, and Smithkline Beecham PLC, Analysis of Proposed Consent Order to Aid Public Comment
no DOI — not checkedFederal Trade Commission [FTC] (2015c): Press Release: FTC Puts Conditions on Novartis AG's Proposed Acquisition of GlaxoSmithKline's Oncology Drugs
no DOI — not checkedguidelines-united-states-department-justice-federal-trade-commission
no DOI — not checkedFDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer
no DOI — not checkedIncorporating dynamic efficiency concerns in merger analysis: The use of innovation markets
no DOI — not checkedref31
no DOI — not checkedref32
no DOI — not checkedDynamic Markets and Dynamic Enforcement -The impact of the digital revolution and globalisation on the enforcement of competition law in Europe
no DOI — not checkedref36
no DOI — not checkedInnovation Markets, Future Markets, or Potential Competition: How should Competition Authorities account for Innovation Competition in
no DOI — not checkedDoes merger control work? A retrospective on U:S: enforcement actions and merger outcomes
no DOI — not checkedInnovation crisis in the pharmaceutical industry? A survey
no DOI — not checkedEuropean Community Antitrust Law: Innovation Markets and High Technology Industries
no DOI — not checkedRoche quietly discontinues Ignyta cancer therapy RXDX-105
no DOI — not checkedAn Innovation in Merger Assessment: The European Commission's Novel Theory of Harm in the Dow/DuPont Merger
no DOI — not checkedProduct Market Definition in the Pharmaceutical Industry
no DOI — not checkedTwo-Drug Combination Approved for Lung Cancers with BRAF Mutations. National Cancer Institute
no DOI — not checkedref50
no DOI — not checkedInforma's $2.6 bln sale of pharma intelligence lifts shares
no DOI — not checkedThe Misapplication of the Innovation Market Approach to Merger Analysis
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-18 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.4349627"><img src="https://citestamp.com/citestamped/10.2139/ssrn.4349627/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.4349627)